Savant Capital LLC Buys 3,787 Shares of Align Technology, Inc. $ALGN

Savant Capital LLC increased its position in Align Technology, Inc. (NASDAQ:ALGN) by 25.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,429 shares of the medical equipment provider’s stock after purchasing an additional 3,787 shares during the period. Savant Capital LLC’s holdings in Align Technology were worth $3,489,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Cromwell Holdings LLC raised its holdings in Align Technology by 2,900.0% in the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 174 shares during the last quarter. SVB Wealth LLC purchased a new stake in shares of Align Technology during the first quarter valued at approximately $36,000. Farther Finance Advisors LLC increased its position in shares of Align Technology by 42.2% during the second quarter. Farther Finance Advisors LLC now owns 310 shares of the medical equipment provider’s stock valued at $59,000 after acquiring an additional 92 shares in the last quarter. Assetmark Inc. raised its holdings in Align Technology by 327.6% in the 2nd quarter. Assetmark Inc. now owns 449 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 344 shares during the last quarter. Finally, Covestor Ltd lifted its position in Align Technology by 18.8% in the 1st quarter. Covestor Ltd now owns 493 shares of the medical equipment provider’s stock valued at $78,000 after acquiring an additional 78 shares in the last quarter. 88.43% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. HSBC lifted their target price on Align Technology from $140.00 to $150.00 in a report on Friday, October 31st. Stifel Nicolaus set a $200.00 price objective on Align Technology in a research report on Thursday, October 30th. Zacks Research upgraded Align Technology from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 30th. Piper Sandler restated an “overweight” rating and set a $200.00 target price (up previously from $190.00) on shares of Align Technology in a research note on Thursday, October 30th. Finally, Morgan Stanley raised their price target on shares of Align Technology from $142.00 to $154.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $175.45.

Align Technology Stock Up 0.8%

Align Technology stock opened at $134.84 on Monday. Align Technology, Inc. has a 52-week low of $122.00 and a 52-week high of $246.19. The company has a market cap of $9.67 billion, a P/E ratio of 26.13, a P/E/G ratio of 1.49 and a beta of 1.84. The business has a 50-day simple moving average of $132.60 and a two-hundred day simple moving average of $160.44.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Wednesday, October 29th. The medical equipment provider reported $2.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.23. Align Technology had a net margin of 9.50% and a return on equity of 14.06%. The company had revenue of $995.69 million for the quarter, compared to the consensus estimate of $980.75 million. During the same quarter last year, the firm posted $2.35 earnings per share. The firm’s revenue was up 1.8% compared to the same quarter last year. Align Technology has set its Q4 2025 guidance at EPS. Research analysts anticipate that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

Align Technology declared that its Board of Directors has approved a share buyback program on Tuesday, August 5th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.